M3, Inc.
2413.TMEDIUMScore: 49.4Satellite · Weight: 7%· Data as of 2026-06-03
Investment Thesis
FY2026 results confirmed re-acceleration thesis: revenue ¥351.4B (+23.3% YoY), OP ¥73.5B (+16.8%), NP ¥49.1B (+21.3%). FY2027 guidance: Revenue ¥400B (+13.8%), OP ¥80B (+8.8%), NP ¥53B. Stock ¥1,474 trades at PE 19.4x trailing / 17.9x forward — cheapest since the -84% drawdown from ATH. Analyst unanimity: 9 buy, 0 sell; average 12M target ¥2,299 (+56% upside). Capital return boost and dividend raised. Core Medical Platform (6.5M doctors, m3.com) still growing. Hybrid hospice/platform model expanding. Caution: Patient Solutions +397% YoY from EWEL acquisition — organic growth likely 12-15% not 23%.
Risk
1) M&A-driven revenue distortion: EWEL acquisition April 2025 inflates headline +23.3%; organic growth ~12-15%. 2) FY2027 guidance decelerating: revenue +13.8% vs FY2026's +23.3% — growth engine slowing. 3) OP margin declining: OP/Revenue = 20.9% (FY2026) vs our old thesis 23.6% — acquisition dilution. 4) Hospice rollup execution risk — physical care facilities have different economics from digital platform. 5) Goldman Sachs downgrade (from original thesis) — monitor if other brokers follow. 6) Forward PE 17.9x modest but not cheap for a decelerating grower.
Monitoring Trigger
If Q1 FY2027 (Jul-Aug 2026) shows organic revenue growth >12% (excluding M&A), HOLD conviction. If Medical Platform segment grows >15% YoY, ADD to 9% — core engine re-accelerating. If another major broker downgrades (2 total), TRIM to 5%. If FY2027 guidance is revised downward at mid-year, EXIT — growth story deteriorating.
Key Dates
Key Metrics
Supply Chain Evidence
| Evidence | Customer | Product | Detail |
|---|---|---|---|
| confirmed | Global pharmaceutical companies (Japan + US + EU) | m3.com medical information platform — pharma marketing to 6.5M doctors | Pharma companies pay for promotional access to doctor network; Pharma Solutions is M3's highest-margin segment |
| confirmed | Japanese hospitals and clinics | medi-job (medical staffing) + carenet (nurse platform) | Medical staffing businesses serve Japanese hospital HR departments; M3 is dominant in Japan doctor-facing digital services |
| confirmed | Japanese elderly / hospice patients | Hospice / nursing home physical care (Patient Solutions rollup) | M3 patient solutions revenue +397% YoY driven by hospice/nursing M&A acquisitions; building physical aging-society infrastructure |